全文获取类型
收费全文 | 265篇 |
免费 | 11篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
妇产科学 | 17篇 |
基础医学 | 18篇 |
口腔科学 | 1篇 |
临床医学 | 5篇 |
内科学 | 44篇 |
皮肤病学 | 2篇 |
神经病学 | 34篇 |
特种医学 | 2篇 |
外科学 | 45篇 |
一般理论 | 1篇 |
预防医学 | 5篇 |
眼科学 | 1篇 |
药学 | 12篇 |
肿瘤学 | 89篇 |
出版年
2022年 | 3篇 |
2021年 | 12篇 |
2020年 | 3篇 |
2019年 | 5篇 |
2018年 | 7篇 |
2017年 | 4篇 |
2016年 | 8篇 |
2015年 | 4篇 |
2014年 | 14篇 |
2013年 | 13篇 |
2012年 | 21篇 |
2011年 | 25篇 |
2010年 | 11篇 |
2009年 | 8篇 |
2008年 | 23篇 |
2007年 | 15篇 |
2006年 | 20篇 |
2005年 | 26篇 |
2004年 | 16篇 |
2003年 | 12篇 |
2002年 | 2篇 |
2001年 | 4篇 |
2000年 | 3篇 |
1999年 | 2篇 |
1998年 | 1篇 |
1996年 | 2篇 |
1995年 | 3篇 |
1993年 | 2篇 |
1992年 | 2篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1981年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有278条查询结果,搜索用时 15 毫秒
1.
Ioannis Dimarakis Aristotle D Protopapas 《European journal of cardio-thoracic surgery》2004,26(4):773-775
Vocal cord palsy after adult cardiac surgery is often attributed to non-surgical mechanisms as tracheal intubation and central venous catheterisation. It may also be caused by injury of the recurrent laryngeal nerves by surgical dissection. We hereby present a review of relevant clinical reports. The cumulative incidence was 1.1% (33 in 2980). Main reported surgical mechanisms of injury were harvesting of internal thoracic artery and topical cold cardioprotection. Bilateral nerve palsy has been lethal on at least one occasion. Where vocal cord injury followed harvesting of the left internal thoracic artery, it was reported ipsilateral to the conduit. 相似文献
2.
3.
N Xiros P Papacostas T Economopoulos G Samelis E Efstathiou E Kastritis H Kalofonos A Onyenadum D Skarlos A Bamias H Gogas D Bafaloukos E Samantas P Kosmidis 《Annals of oncology》2005,16(5):773-779
BACKGROUND: In the present phase II multicenter study, we assessed the efficacy and tolerability of the combination of gemcitabine and carboplatin in patients with advanced pancreatic cancer. PATIENTS AND METHODS: Patients with previously untreated, locally advanced or metastatic pancreatic cancer were treated with gemcitabine 800 mg/m(2) on days 1 and 8 and carboplatin at an AUC of 4 on day 8 of a 3-week cycle, for a total of six cycles. Primary end points were response rate and clinical benefit; secondary end points were, survival, time to progression (TTP) and toxicity. RESULTS: A total of 50 patients were enrolled in the study, 47 of whom were eligible for treatment. The median age was 63 years (range 34-76) and the median Karnofsky performance status (PS) was 80%. Patients received a median of six cycles (range 1-11). Among 35 patients evaluable for response, eight (17%) achieved partial response; 15 (32%) and 12 (25%) patients had stable and progressive disease, respectively. The median overall survival was 7.4 months; the median TTP was 4.4 months and the 1-year survival was 28%. The observed clinical benefit response was remarkable. After the second cycle of chemotherapy, 21 of 31 (68%) patients experienced pain improvement and reduced analgesic consumption. At the same time, 35% and 56% of our patients significantly improved their Karnofsky PS and weight, respectively. Overall, the treatment was well tolerated. The most common grade 3-4 toxicities were hematological, including 8% anemia, 6% neutropenia and 13% thrombocytopenia. CONCLUSIONS: The combination of gemcitabine plus carboplatin is a moderately active treatment for patients with locally advanced and metastatic pancreatic cancer. This regimen has an acceptable toxicity profile and provides a significant clinical benefit, and hence warrants further investigation. 相似文献
4.
H P Kalofonos G Aravantinos P Kosmidis P Papakostas T Economopoulos M Dimopoulos D Skarlos A Bamias D Pectasides S Chalkidou M Karina A Koutras E Samantas C Bacoyiannis G F Samelis G Basdanis F Kalfarentzos G Fountzilas 《Annals of oncology》2005,16(6):869-877
BACKGROUND: Irinotecan (IRI) and oxaliplatin (OXA) are effective in the treatment of colorectal cancer. Previously untreated patients with advanced colorectal carcinoma (CRC) were randomly assigned to receive IRI plus leucovorin (LV)/5-fluorouracil (5-FU), or OXA plus LV/5-FU in order to compare the response rates, time-to-tumor progression, overall survival rates, and toxicity profiles of these two agents. MATERIALS AND METHODS: From January 1999 to February 2002, 295 patients were randomized to receive either IRI/LV/5-FU or OXA/LV/5-FU. The treatment schedules consisted of weekly IRI 70 mg/m(2) or OXA 45 mg/m(2) plus LV 200 mg/m(2) followed immediately by intravenous bolus 5-FU 450 mg/m(2) for 6 weeks, followed by a 2-week rest period. Treatment was continued for up to four cycles or until disease progression, unacceptable toxicity or patient refusal. RESULTS: There were no significant differences between the study arms in the overall response rate (33% with IRI/LV/5-FU versus 32% with OXA/LV/5-FU based on responses demonstrated on a single evaluation; 23% with IRI/LV/5-FU versus 22.3% with OXA/LV/5-FU based on responses confirmed according to WHO criteria) median time to progression (8.9 versus 7.6 months), and median overall survival (17.6 versus 17.4 months). Toxicity profiles (grades 3 and 4) were similar in the IRI and OXA arms (diarrhea 12.3% and 9.8%, neutropenia 8.2% and 4.9%, and febrile neutropenia 1.4% and 1.4%, respectively), with the exception of grade 3 sensory neuropathy, which almost exclusively occurred in the OXA arm (0% versus 5.6%; P=0.003, Fisher's exact test). CONCLUSION: The IRI/LV/5-FU and OXA/LV/5-FU regimens demonstrated equally substantial efficacies and manageable toxicity profiles in the first-line treatment of patients with advanced CRC. However, IRI/LV/5-FU may be the preferable regimen to avoid significant neurotoxicity associated with OXA-LV/5-FU. 相似文献
5.
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. 总被引:23,自引:0,他引:23
Aristotle Bamias Efstathios Kastritis Christina Bamia Lia A Moulopoulos Ioannis Melakopoulos George Bozas Vassiliki Koutsoukou Dimitra Gika Athanasios Anagnostopoulos Christos Papadimitriou Evagelos Terpos Meletios A Dimopoulos 《Journal of clinical oncology》2005,23(34):8580-8587
PURPOSE: Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid. We studied the incidence, characteristics, and risk factors for the development of ONJ among patients treated with bisphosphonates for bone metastases. PATIENTS AND METHODS: ONJ was assessed prospectively since July 2003. The first bisphosphonate treatment among patients with ONJ was administered in 1997. Two hundred fifty-two patients who received bisphosphonates since January 1997 were included in this analysis. RESULTS: Seventeen patients (6.7%) developed ONJ: 11 of 111 (9.9%) with multiple myeloma, two of 70 (2.9%) with breast cancer, three of 46 (6.5%) with prostate cancer, and one of 25 (4%) with other neoplasms (P = .289). The median number of treatment cycles and time of exposure to bisphosphonates were 35 infusions and 39.3 months for patients with ONJ compared with 15 infusions (P < .001) and 19 months (P = .001), respectively, for patients with no ONJ. The incidence of ONJ increased with time to exposure from 1.5% among patients treated for 4 to 12 months to 7.7% for treatment of 37 to 48 months. The cumulative hazard was significantly higher with zoledronic acid compared with pamidronate alone or pamidronate and zoledronic acid sequentially (P < .001). All but two patients with ONJ had a history of dental procedures within the last year or use of dentures. CONCLUSION: The use of bisphosphonates seems to be associated with the development of ONJ. Length of exposure seems to be the most important risk factor for this complication. The type of bisphosphonate may play a role and previous dental procedures may be a precipitating factor. 相似文献
6.
7.
8.
Bamias A Basdanis G Xanthakis I Pavlidis N Fountzilas G 《Journal of gastrointestinal cancer》2005,36(1):29-38
Background. Although the TNM system is useful in predicting survival in resected colorectal cancer, heterogeneity within the same stages
regarding prognosis exists. We are presenting a pooled analysis of prognostic factors from two randomized studies of adjuvant
treatment conducted by the Hellenic Cooperative Oncology Group.
Patients and Methods. Patients with stage II or III colon (n=279) or rectal (n=220) cancer were included in this analysis. Following surgery, patients received: 5-fluorouracil/leucovorin (5-FU/LV) (n=135), 5-FU/LV and interferon Alfa-2a (IFNA-2a) (n=138), 5-FU/LV and pelvic chemoradiotherapy (n=106), and pelvic chemoradiotherapy alone (n=108).
Results. Median follow up was 92 mo. The number of involved lymph nodes (LNs), tumor differentiation, and the presence of regional
implants were independent prognostic factors for both OS and TTP, while nerve invasion was only significant for TTP. Patients
were stratified into three prognostic groups (low-risk: no LNs and grade 1/2; high-risk: >3 LNs and grade 3/4; intermediate-risk:
remaining patients) with distinct differences in 5-yr survival (84.7% vs 57.6% vs 32.4%) and 5-yr TTP (81.2% vs 54.5% vs 28.6%).
Conclusion. The combination of clinicopathological prognostic factors can be more informative than the traditional TNM staging system.
Such stratification may be necessary in randomized trials and could be useful in deciding the most appropriate adjuvant treatment
strategies. 相似文献
9.
Alastair J. Flint Anthony J. Rothschild Ellen M. Whyte George S. Alexopoulos Benoit H. Mulsant Patricia Marino Samprit Banerjee Cristina D. Pollari Yiyuan Wu Aristotle N. Voineskos Barnett S. Meyers 《The American journal of geriatric psychiatry》2021,29(7):645-654
ObjectiveTo examine the effect of older versus younger age on change in anthropometric and metabolic measures during extended treatment of psychotic depression with sertraline plus olanzapine.MethodsTwo hundred and sixty-nine men and women aged 18–85 years with an episode of psychotic depression were treated with open-label sertraline plus olanzapine for up to 12 weeks. Participants who remained in remission following an 8-week stabilization phase were eligible to participate in a 36-week randomized controlled trial (RCT) that compared the efficacy and tolerability of sertraline plus olanzapine with sertraline plus placebo. Weight, waist circumference and plasma lipids, glucose, HbA1c, and insulin were measured at regular intervals during the acute, stabilization and randomized phases of the study. Linear mixed models were used to analyze the trajectories of anthropometric and metabolic measures.ResultsParticipants aged 60 years or older experienced less weight gain and less increase in cholesterol during the combined acute and stabilization phases of the study compared with those aged 18–59 years. At the acute-stabilization termination visit, mean weight in older participants was 6.5 lb. less than premorbid weight, whereas it was 17.9 lb. more than premorbid weight in younger participants. In the RCT, there was a significant interaction of treatment and age group for the trajectory of weight, but the post hoc tests that compared age groups within each treatment arm were not statistically significant. There were no clinically significant differences between younger and older participants in glycemic measures.ConclusionOlder patients with psychotic depression experienced less increase in weight and total cholesterol than their younger counterparts during acute and stabilization treatment with sertraline plus olanzapine. In the older group, weight gained during the acute and stabilization phases appeared to be partial restoration of weight lost during the index episode of depression, whereas weight gain in younger participants was not. 相似文献
10.
Ioannis Papaconstantinou Evanthia Zampeli Dionysios Dellaportas Charalambos Giannopoulos Maria Sotiropoulou George Polymeneas Giorgos Bamias Spyros Michopoulos 《Clinical journal of gastroenterology》2014,7(2):132-135
Pouchitis occurs in up to one half of patients after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). Cytomegalovirus (CMV) and Clostridium difficile are among the commonest secondary identifiable etiologies. A 17-year-old male with ulcerative colitis underwent IPAA due to refractory disease. Nine months later he experienced bloody diarrhea and fever. Laboratory testing and endoscopy confirmed pouch inflammation. Testing for C. difficile toxins A and B was positive. Histology revealed affluent inclusion bodies and immunohistochemistry detected reactivity against CMV protein. Treatment with metronidazole and vancomycin offered partial improvement, whereas the addition of gancyclovir led to a successful recovery. One month after completion of treatment symptoms recurred. Repeat testing precluded an identifiable infectious cause and the diagnosis of idiopathic chronic pouchitis was established. The patient is currently on maintenance treatment with the probiotic compound VSL#3. 相似文献